Shopping Cart 0
Cart Subtotal
AED 0

CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp (CTIC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Cell Therapeutics Acquires Pacritinib From S*BIO 11

Venture Financing 13

CTI BioPharma Announces Venture Debt Financing 13

Licensing Agreements 14

CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15

Equity Offering 17

CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17

CTI BioPharma Raises USD69 Million in Public Offering of Shares 18

CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20

CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22

CTI BioPharma Raises USD50 Million in Public Offering of Shares 24

CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26

CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28

Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30

Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32

Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34

CTI BioPharma Corp-Key Competitors 36

CTI BioPharma Corp-Key Employees 37

CTI BioPharma Corp-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Nov 01, 2018: CTI BioPharma reports third quarter 2018 financial results 39

Aug 02, 2018: CTI BioPharma reports second quarter 2018 financial results 40

May 03, 2018: CTI BioPharma Reports First Quarter 2018 Financial Results 42

Mar 07, 2018: CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results 43

Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45

Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 46

May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 47

Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 48

Corporate Communications 50

Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 50

Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 51

Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 52

Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 53

Product News 54

01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 54

Product Approvals 56

Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 56

Clinical Trials 57

Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 57

Other Significant Developments 59

Jan 25, 2018: CTI BioPharma Provides Corporate and European Regulatory Update 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cell Therapeutics Acquires Pacritinib From S*BIO 11

CTI BioPharma Announces Venture Debt Financing 13

CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15

CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17

CTI BioPharma Raises USD69 Million in Public Offering of Shares 18

CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20

CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22

CTI BioPharma Raises USD50 Million in Public Offering of Shares 24

CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26

CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28

Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30

Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32

Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34

CTI BioPharma Corp, Key Competitors 36

CTI BioPharma Corp, Key Employees 37

CTI BioPharma Corp, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CTI BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp (CTIC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Cell Therapeutics Acquires Pacritinib From S*BIO 11

Venture Financing 13

CTI BioPharma Announces Venture Debt Financing 13

Licensing Agreements 14

CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15

Equity Offering 17

CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17

CTI BioPharma Raises USD69 Million in Public Offering of Shares 18

CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20

CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22

CTI BioPharma Raises USD50 Million in Public Offering of Shares 24

CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26

CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28

Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30

Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32

Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34

CTI BioPharma Corp-Key Competitors 36

CTI BioPharma Corp-Key Employees 37

CTI BioPharma Corp-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Nov 01, 2018: CTI BioPharma reports third quarter 2018 financial results 39

Aug 02, 2018: CTI BioPharma reports second quarter 2018 financial results 40

May 03, 2018: CTI BioPharma Reports First Quarter 2018 Financial Results 42

Mar 07, 2018: CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results 43

Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45

Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 46

May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 47

Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 48

Corporate Communications 50

Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 50

Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 51

Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 52

Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 53

Product News 54

01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 54

Product Approvals 56

Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 56

Clinical Trials 57

Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 57

Other Significant Developments 59

Jan 25, 2018: CTI BioPharma Provides Corporate and European Regulatory Update 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CTI BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cell Therapeutics Acquires Pacritinib From S*BIO 11

CTI BioPharma Announces Venture Debt Financing 13

CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15

CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17

CTI BioPharma Raises USD69 Million in Public Offering of Shares 18

CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20

CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22

CTI BioPharma Raises USD50 Million in Public Offering of Shares 24

CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26

CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28

Cell Therapeutics Completes Private Placement Of Preferred Stock For USD 15 Million 30

Cell Therapeutics Completes Public Offering Of Preferred Stock For USD 60 Million 32

Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For USD 15 Million 34

CTI BioPharma Corp, Key Competitors 36

CTI BioPharma Corp, Key Employees 37

CTI BioPharma Corp, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CTI BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.